Effect of Nutrition Ingredients on Microbiota Modulation

Inclusion Criteria: 1. Subjects willing and able to give written informed consent and to understand, to participate and to comply with the clinical study requirements; 2. Be between 20 and 50 years of age; 3. Has a BMI of between 18.5 - 30 Kg/m2; 4. Has a stable body weight (\< 5% change) over the past 3-months; 5. Is in general good health, as determined by the investigator; 6. Willing to avoid consuming dietary supplements, prebiotic, probiotic, dietary or fibre rich supplements within 4 weeks prior to baseline visit, until the end of the study; 7. Willing to avoid liver consumption during the intervention 8. Maintain current level of physical activity; 9. Women of child-bearing potential using a non-hormonal contraceptive (e.g. IUD); 10. Willing to consume the investigational product daily for the duration of the study. Exclusion Criteria: 1. Females are pregnant, lactating or wish to become pregnant during the study. 2. Are hypersensitive to any of the components of the test product; 3. Has taken antibiotics within the previous 3 months; 4. Has a history of drug and/or alcohol abuse at the time of enrolment; 5. Consumes greater than 2 servings/day of alcohol (e.g. \>28 g ethanol/day); 6. Is a smoker; 7. Has made any major dietary changes in the past 3 months; 8. Subject is planning a sun or ski holiday over the duration of the study; 9. Planned major changes in life style (i.e. diet, dieting, exercise level, travelling) during the duration of the study; 10. Has an eating disorder; 11. Is vegetarian/vegan diet or has food allergies or other issues with foods that would preclude intake of the study products; 12. Is using fibre supplements or enemas; 13. Has a high fiber diet (i.e. \>30 g) based on FFQ; 14. Has an active gastrointestinal disorder or previous gastrointestinal surgery, 15. If taking chronic medications (e.g., anti-hypertensive medications), they must have been taking the product for at least two months prior to screening and agree to maintain the same dosage throughout the study; 16. Has a metabolic, psychiatric, or gastrointestinal disease (i.e., diarrhoea, Crohn's disease, ulcerative colitis, irritable bowel syndrome, diverticulosis, stomach or duodenal ulcers, diabetes, hepatitis, HIV, cancer, etc.), with a history of such diseases; 17. Are severely immunocompromised (HIV positive, transplant patient, on antirejection medications, on a steroid for \>30 days, or chemotherapy or radiotherapy within the last year); 18. Experiences alarm features such as weight loss, rectal bleeding, recent change in bowel habit (\<3 months) or abdominal pain; 19. Have a malignant disease or any concomitant end-stage organ disease; 20. Individuals who, in the opinion of the investigator, are considered to be poor attendees or unlikely for any reason to be able to comply with the trial; 21. Subjects may not be receiving treatment involving experimental drugs. If the subject has been in a recent experimental trial, these must have been completed not less than 60 days prior to this study.